"And then secondly, Vas, maybe one for you. With tislelizumab and the BeiGene deal, obviously, this is exporting innovation out of China for one of the first products to do so. So is there a potential challenge here in terms of exporting the product at a lower price point when it comes to negotiating pricing agreements with governments globally? Or is the lower price points in China potentially something you could use to your advantage when it comes to transferring the value into potential combinations of your next-generation assets? So thinking things such as TIM-3, SHP2, CD73, et cetera. So it would be useful to get some context there."